Semaglutide 2.4mg

DRUG3 trials

Sponsors

Loma Linda University, The University of Texas Health Science Center, Houston, Nordsjaellands Hospital

Conditions

Cigarette SmokingGlycemic Control for Diabetes MellitusInsulin Sensitivity/ResistanceLipidomicsMetabolomicsObesityObesity in DiabetesObesity/Therapy

Phase 2

Semaglutide for Post-Smoking Cessation Weight Management

RecruitingNCT06173778

The University of Texas Health Science Center, HoustonCigarette Smoking, Obesity, Overweight

Start: 2024-04-23End: 2026-08-01Target: 197Updated: 2026-02-11

Phase 3

Latino Semaglutide Study

CompletedNCT05087342

Loma Linda UniversityObesity, Obesity; Drug, Overweight or Obesity +3

Start: 2022-12-13End: 2024-05-29Updated: 2024-10-15

Semaglutide Treatment in Type 1 Diabetes

Not yet recruitingNCT06909006

Nordsjaellands HospitalGlycemic Control for Diabetes Mellitus, Insulin Sensitivity/Resistance, Lipidomics +6

Start: 2025-10-31End: 2028-06-30Target: 122Updated: 2025-08-08

Related Papers

A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.

2025-06-18